Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CSU Clear all

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Coral Gables, Florida • Boise, Idaho • St Louis, Missouri + 6 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Nucala; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Urticaria
Interventions: GDC-0853, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more

Conditions: Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
Interventions: CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment, HS low dose treatment, HS medium dose treatment, HS high dose treatment; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Fountain Valley, California • North Miami Beach, Florida • Tampa, Florida + 6 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 (blinded), placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 11
States / cities: Bakersfield, California • San Diego, California • Miami, Florida + 8 more

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: BLU-808, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 23 more

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: EDP-978, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more

Conditions: Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: Not listed
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2050
U.S. locations: 54
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more

Conditions: Chronic Spontaneous Urticaria
Interventions: CDX-0159, Normal Saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more

Conditions: Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions: KPL-716, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more

Conditions: Chronic Idiopathic Urticaria
Interventions: etanercept, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Standard of Care; Biological · Other
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 39 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 37 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Benralizumab, Placebo and Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more

Conditions: Chronic Idiopathic Urticaria
Interventions: benralizumab, placebo; Biological
Lead sponsor: Jonathan A. Bernstein, MD; Other
Eligibility: 19 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Spontaneous Urticaria
Interventions: QGE031, Omalizumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more

Conditions: Urticaria Chronic
Interventions: Omalizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 63
States / cities: Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more

Conditions: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: North Miami Beach, Florida • Glenview, Illinois

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 (blinded), Placebo, LOU064 (open-label); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 30
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 27 more

Conditions: Chronic Spontaneous Urticaria, CSU
Interventions: Ritlecitinib; Drug
Lead sponsor: Ahuva D Cices; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

Remibrutinib in Real-world Clinical Practice

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Etanercept for the Treatment of Chronic Urticaria

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria